ArticleBMC molecular and cell biology2026
Differential phosphorylation of PHIP phosphopeptides with implications in insulin signaling.
Article in BMC molecular and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPHIP (PH Interacting Protein) is an Insulin Receptor Substrate 1 (IRS1) interactor protein that binds to acetylated IRS1 through its bromodomain. Due to its involvement in insulin signaling pathway, it is implicated in various malignancies and metabolic disorders. Despite this role, the phosphoregulatory network governing PHIP activity is understudied. Therefore, current study aimed to elucidate the landscape of PHIP phosphorylation and its functional significance in insulin signaling by employing a global phosphoproteomic data integration and harmonization strategy.
resultsA total of 1008 human phosphoproteomics datasets were used to gather 412 differential regulation datasets exhibiting differential abundance of PHIP phosphopeptides. Seven predominant phosphorylation sites of PHIP (S879, S880, S881, S1281, S1283, S1315, and S1783) were most frequently detected in phosphoproteomics data derived from cell lines and tissue samples. Further, conserved, statistically robust inter-protein co-differential regulation analysis as compared to differential phosphorylation of PHIP showed several upstream kinases (CHEK2, CLK1 and ATM) and interactors (SMARCA4 and NCOA5), which are known to be involved in the insulin signaling pathway. IRS1 and IRS2, which definitively modulate insulin signaling, also showed significant co-differential regulation with PHIP phosphorylation. When cross-validated with CPTAC and cProSite data, PHIP, SMARCA4 and CHEK2 showed differential protein abundance and phosphorylation status in Hepatocellular Carcinoma samples, further linking insulin signaling and liver cancers in connection to PHIP phosphorylation.
conclusionsThis phosphorylation-centric study suggests the role of phosphorylated PHIP in insulin signaling pathway through modulation and co-differential phosphorylation of key proteins, paving the way for a robust and replicable approach in elucidating putative targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.